# OnCo record paper-keynote-859-lancet-oncol-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-859-lancet-oncol-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-859-lancet-oncol-2023" ;
  schema:name "KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer"@en ;
  schema:description "Adding pembrolizumab to platinum-fluoropyrimidine chemotherapy lengthened survival in HER2-negative advanced gastric cancer, with the largest gain in tumours with a PD-L1 combined positive score of 10 or more, confirming chemo-immunotherapy as first-line standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-859-lancet-oncol-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(23)00515-6>, <https://pubmed.ncbi.nlm.nih.gov/37875143/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(23)00515-6> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Rha SY, Oh DY, Yañez P, et al." ;
  onco:cancers <https://onco.cc/cancers/gastric-pdl1-high/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-859/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .